Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa

Factor XI as a Target for New Anticoagulants

(2021) James C. Fredenburgh et al.   Hamostaseologie

Abelacimab for Prevention of Venous Thromboembolism

(2021) Peter Verhamme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty

(2020) Jeffrey I. Weitz et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans

(2019) Alexander W. Koch et al.   BLOOD

The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials

(2019) Emma P. DeLoughery et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants

(2017) Gordon F. Tomaselli et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Factor XI as a Therapeutic TargetHighlights

(2016) David Gailani et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

(2015) S. Kaatz et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

(2015) Harry R. Büller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Factor XI deficiency--resolving the enigma?

(2009) P. H. B. Bolton-Maggs   Hematology-American Society of Hematology Education Program